Background As the overdose crisis continues in the US and Canada, opioid use disorder
(OUD) treatment outcomes for people with co-occurring psychiatric disorders are not well …

Introduction Recent US trends demonstrate sharp rises in adverse opioid-related health
outcomes, including opioid use disorder (OUD), overdose, and death. Yet few affected …

Background Potential differences in buprenorphine treatment outcomes across various
treatment settings are poorly characterized in multi-state administrative data. We thus …

Introduction Current evidence indicates that buprenorphine is a highly effective treatment for
opioid use disorder (OUD), though premature medication discontinuation is common …

Background Facing an epidemic of opioid-related mortality, many government health
departments, insurers, and treatment providers have attempted to expand patient access to …

Importance Despite prevalent polysubstance use, treatment patterns and outcomes for
individuals with opioid use disorder (OUD) and cooccurring substance use disorders (SUD) …

Objective: This study examined factors related to retention in buprenorphine treatment for
opioid use disorder (OUD) among privately insured patients. Methods: Patients with OUD …

Objective: Although buprenorphine treatment reduces risk of overdose and death in opioid
use disorder, most patients discontinue treatment within a few weeks or months. Adverse …

Background and Objectives Previous research has been inconclusive about whether opioid‐
dependent patients with psychiatric comorbidities have shorter treatment retention and …

Aims To investigate whether reduction in opioid use differs when treated by either
buprenorphine–naloxone (BUP) or methadone (MET) among adults with comorbid opioid …